Global Development of CHP Cancer Protein Vaccines
Drug Discovery for Multifunctional Cancer DNA Vaccines
Drug Discovery of “Therapeutics for Immune Diseases” by Exploring Immune Regulatory Mechanism
ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US.
ImmunoFrontier completed the CSR of Phase I Study of CHP-NY-ESO-1 in Patients with Refractory Esophageal Cancer Expressing NY-ESO 1 in Japan.
FDA approved Phase I Study of IMF-001 in US.
ImmunoFrontier filed an IND application of IMF-001 for Phase I Study in US.
ImmunoFrontier filed an Application of CHP-NY-ESO-1 for Phase I Study with PMDA to develop for esophageal cancer.
CHP-NY-ESO-1 project was chosen for NIBIO’s “Practical Application Research Supporting Program for Medicine and Medical Device”.